Ranibizumab is an anti-VEGF-A monoclonal antibody fragment that reduces the bioactivity of vitreous and prevents the development of PVR.
The National Eye Institute of NIH, Canadian Institute of Health Research, Department of Defense and Massachusetts Lions Foundation funded the study.
More Articles on Ophthalmology:
NovaBay Pharmaceuticals Begins Patient Trial of Pink-Eye Treatment
FDA Approves PROLENSA from Bausch + Lomb
LENSAR Laser System Earns FDA 510(k) Clearance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
